813 Stock Overview
Dezhan Healthcare Company Limited engages in the research and development, manufacture, and sale of cardiovascular and cerebrovascular drugs in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Dezhan Healthcare Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥2.73 |
| 52 Week High | CN¥4.70 |
| 52 Week Low | CN¥2.23 |
| Beta | 0.40 |
| 1 Month Change | -9.00% |
| 3 Month Change | -6.51% |
| 1 Year Change | -13.06% |
| 3 Year Change | -44.29% |
| 5 Year Change | -75.60% |
| Change since IPO | -72.26% |
Recent News & Updates
Shareholder Returns
| 813 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -5.2% | -1.5% | -0.4% |
| 1Y | -13.1% | -16.0% | -17.6% |
Return vs Industry: 000813 exceeded the CN Pharmaceuticals industry which returned -15.9% over the past year.
Return vs Market: 000813 exceeded the CN Market which returned -17.8% over the past year.
Price Volatility
| 813 volatility | |
|---|---|
| 813 Average Weekly Movement | 6.9% |
| Pharmaceuticals Industry Average Movement | 7.9% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.4% |
Stable Share Price: 000813 has not had significant price volatility in the past 3 months.
Volatility Over Time: 000813's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | 1,002 | Wei Liu | www.dezhanhealthcare.com |
Dezhan Healthcare Company Limited engages in the research and development, manufacture, and sale of cardiovascular and cerebrovascular drugs in the People’s Republic of China. The company’s products include Vastatin Calcium Tablets (Nile), Trimetazidine Hydrochloride capsules, Fanle type I and II tablets, Azathioprine tablets, Amiodarone Hydrochloride tablets, Hydroxyurea tablets, Colchicine tablets, etc. It also offers biological peptide products, food and beverages, cosmetics, and other products. The company was founded in 1980 and is based in Beijing, the People’s Republic of China.
Dezhan Healthcare Company Limited Fundamentals Summary
| 813 fundamental statistics | |
|---|---|
| Market cap | CN¥5.91b |
| Earnings (TTM) | CN¥83.31m |
| Revenue (TTM) | CN¥498.09m |
70.9x
P/E Ratio11.9x
P/S RatioIs 813 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 813 income statement (TTM) | |
|---|---|
| Revenue | CN¥498.09m |
| Cost of Revenue | CN¥223.13m |
| Gross Profit | CN¥274.96m |
| Other Expenses | CN¥191.64m |
| Earnings | CN¥83.31m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 25, 2024
| Earnings per share (EPS) | 0.038 |
| Gross Margin | 55.20% |
| Net Profit Margin | 16.73% |
| Debt/Equity Ratio | 0.02% |
How did 813 perform over the long term?
See historical performance and comparison